[{"id":"29314cf0-3dae-48bb-bacc-9547b377d15c","acronym":"","url":"https://clinicaltrials.gov/study/NCT07471789","created_at":"2026-03-28T01:43:57.744Z","updated_at":"2026-03-28T01:43:57.744Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).","source_id_and_acronym":"NCT07471789","lead_sponsor":"Gyala Therapeutics","biomarkers":" CD8 • CD4","pipe":"","alterations":" ","tags":["CD8 • CD4"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 02/04/2026","start_date":" 02/04/2026","primary_txt":" Primary completion: 05/31/2029","primary_completion_date":" 05/31/2029","study_txt":" Completion: 02/04/2031","study_completion_date":" 02/04/2031","last_update_posted":"2026-03-13"},{"id":"842583e2-8e92-49fc-94d6-2f73865d1b14","acronym":"","url":"https://clinicaltrials.gov/study/NCT07203352","created_at":"2025-10-04T08:00:11.817Z","updated_at":"2025-10-04T08:00:11.817Z","phase":"Phase 3","brief_title":"Efficacy of Targeted Drugs Combined With Chemotherapy in the Treatment of T-ALL","source_id_and_acronym":"NCT07203352","lead_sponsor":"Nanfang Hospital, Southern Medical University","biomarkers":" ABL2","pipe":"","alterations":" ","tags":["ABL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib"],"overall_status":"Recruiting","enrollment":" Enrollment 154","initiation":"Initiation: 10/01/2025","start_date":" 10/01/2025","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/30/2026","study_completion_date":" 12/30/2026","last_update_posted":"2025-10-02"},{"id":"1d2cc1b3-1db7-4ec6-826d-f95392ccf5c1","acronym":"","url":"https://clinicaltrials.gov/study/NCT07012447","created_at":"2025-06-14T13:57:18.760Z","updated_at":"2025-06-14T13:57:18.760Z","phase":"Phase 2","brief_title":"Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations","source_id_and_acronym":"NCT07012447","lead_sponsor":"yuejun Liu","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • azacitidine"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 04/01/2025","start_date":" 04/01/2025","primary_txt":" Primary completion: 04/01/2027","primary_completion_date":" 04/01/2027","study_txt":" Completion: 05/01/2028","study_completion_date":" 05/01/2028","last_update_posted":"2025-06-10"},{"id":"0a6aefb7-2166-498d-888e-ed54ef581ee3","acronym":"","url":"https://clinicaltrials.gov/study/NCT00792948","created_at":"2021-01-18T03:00:33.783Z","updated_at":"2025-02-25T12:25:29.112Z","phase":"Phase 2","brief_title":"Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT00792948","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABL1 • BCR • CD22 • CD5 • CD79A • MME • CD7 • ANPEP • MPO","pipe":"","alterations":" ","tags":["ABL1 • BCR • CD22 • CD5 • CD79A • MME • CD7 • ANPEP • MPO"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • methotrexate • vincristine • sirolimus • leucovorin calcium • Hemady (dexamethasone tablets) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 97","initiation":"Initiation: 09/01/2009","start_date":" 09/01/2009","primary_txt":" Primary completion: 06/01/2016","primary_completion_date":" 06/01/2016","study_txt":" Completion: 01/06/2026","study_completion_date":" 01/06/2026","last_update_posted":"2025-02-24"},{"id":"2d611a75-574e-482e-91b3-3bf96d4e7ace","acronym":"CATCHAML","url":"https://clinicaltrials.gov/study/NCT04318678","created_at":"2021-01-18T20:55:40.221Z","updated_at":"2025-02-25T12:27:32.189Z","phase":"Phase 1","brief_title":"CD123-Directed Autologous T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)","source_id_and_acronym":"NCT04318678 - CATCHAML","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" CD123 • IL3RA","pipe":"","alterations":" ","tags":["CD123 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • fludarabine IV • mesna • CD123-CAR T cell therapy • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 07/29/2020","start_date":" 07/29/2020","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2025-02-24"},{"id":"ff4e0c3b-845b-4c81-ada0-12dd4b76209c","acronym":"","url":"https://clinicaltrials.gov/study/NCT06777979","created_at":"2025-02-25T13:57:28.881Z","updated_at":"2025-02-25T13:57:28.881Z","phase":"Phase 1","brief_title":"CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT06777979","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" CD22","pipe":"","alterations":" ","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • mesna"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/01/2025","start_date":" 05/01/2025","primary_txt":" Primary completion: 01/01/2030","primary_completion_date":" 01/01/2030","study_txt":" Completion: 01/01/2031","study_completion_date":" 01/01/2031","last_update_posted":"2025-02-20"},{"id":"39a3ce34-fc3f-4772-a312-5b10b9a2eacf","acronym":"","url":"https://clinicaltrials.gov/study/NCT00390793","created_at":"2022-04-24T08:54:27.800Z","updated_at":"2025-02-25T14:06:37.175Z","phase":"Phase 2","brief_title":"Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.","source_id_and_acronym":"NCT00390793","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • vincristine • prednisone • daunorubicin • Starasid (cytarabine ocfosfate)"],"overall_status":"Completed","enrollment":" Enrollment 107","initiation":"Initiation: 09/28/2006","start_date":" 09/28/2006","primary_txt":" Primary completion: 02/02/2024","primary_completion_date":" 02/02/2024","study_txt":" Completion: 02/02/2024","study_completion_date":" 02/02/2024","last_update_posted":"2025-02-17"},{"id":"4448c756-db79-4484-aae6-303e6174097b","acronym":"AALL1631","url":"https://clinicaltrials.gov/study/NCT03007147","created_at":"2021-01-18T14:47:39.557Z","updated_at":"2025-02-25T14:50:25.163Z","phase":"Phase 3","brief_title":"Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT03007147 - AALL1631","lead_sponsor":"Children's Oncology Group","biomarkers":" ABL1 • BCR • PDGFRA • PDGFRB • IKZF1 • CSF1R","pipe":" | ","alterations":" BCR-ABL1 fusion • ABL1 fusion","tags":["ABL1 • BCR • PDGFRA • PDGFRB • IKZF1 • CSF1R"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCR-ABL1 fusion • ABL1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • methotrexate • vincristine • daunorubicin • dexamethasone • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • thioguanine • Hemady (dexamethasone tablets) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexrazoxane • levoleucovorin calcium • prednisolone"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 475","initiation":"Initiation: 08/08/2017","start_date":" 08/08/2017","primary_txt":" Primary completion: 09/30/2027","primary_completion_date":" 09/30/2027","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-13"},{"id":"96dc9fc0-af06-4f1e-b4e5-802d917774dd","acronym":"","url":"https://clinicaltrials.gov/study/NCT05761171","created_at":"2023-03-09T15:01:28.014Z","updated_at":"2025-02-25T15:13:22.304Z","phase":"Phase 2","brief_title":"A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia","source_id_and_acronym":"NCT05761171","lead_sponsor":"Children's Oncology Group","biomarkers":" KMT2A","pipe":" | ","alterations":" MLL rearrangement","tags":["KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • methotrexate • vincristine • Revuforj (revumenib) • Oncaspar liquid (pegaspargase) • fludarabine IV • Asparlas (calaspargase pegol-mknl) • Starasid (cytarabine ocfosfate)"],"overall_status":"Recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 01/08/2024","start_date":" 01/08/2024","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-13"},{"id":"357b4d1c-0cfa-4162-a300-61812b45530e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05602194","created_at":"2022-11-02T14:56:42.944Z","updated_at":"2025-02-25T15:20:06.675Z","phase":"Phase 3","brief_title":"Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma","source_id_and_acronym":"NCT05602194","lead_sponsor":"Children's Oncology Group","biomarkers":" CRLF2 • PNPLA3 • SOD2","pipe":"","alterations":" ","tags":["CRLF2 • PNPLA3 • SOD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Oncaspar liquid (pegaspargase) • Asparlas (calaspargase pegol-mknl)"],"overall_status":"Recruiting","enrollment":" Enrollment 440","initiation":"Initiation: 08/24/2023","start_date":" 08/24/2023","primary_txt":" Primary completion: 06/30/2028","primary_completion_date":" 06/30/2028","study_txt":" Completion: 12/30/2028","study_completion_date":" 12/30/2028","last_update_posted":"2025-02-12"},{"id":"984a9572-0002-4941-9116-d4a0af76671f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05268003","created_at":"2022-03-07T18:53:49.340Z","updated_at":"2025-02-25T15:27:17.213Z","phase":"Phase 2","brief_title":"A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT05268003","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Iclusig (ponatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 06/07/2022","start_date":" 06/07/2022","primary_txt":" Primary completion: 10/05/2026","primary_completion_date":" 10/05/2026","study_txt":" Completion: 10/05/2026","study_completion_date":" 10/05/2026","last_update_posted":"2025-02-10"},{"id":"fbd6bc02-c103-44b1-a7a6-46bf853b12db","acronym":"","url":"https://clinicaltrials.gov/study/NCT03808610","created_at":"2021-01-18T18:49:14.679Z","updated_at":"2025-02-25T15:34:18.507Z","phase":"Phase 1/2","brief_title":"Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT03808610","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BCL2","pipe":" | ","alterations":" BCL2 expression","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Rituxan (rituximab) • cytarabine • cyclophosphamide • methotrexate • vincristine • Oncaspar liquid (pegaspargase) • Truxima (rituximab-abbs) • nelarabine • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • Novex (rituximab biosimilar) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 04/03/2019","start_date":" 04/03/2019","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-10"},{"id":"2d8fede0-d3af-4a3f-8d61-856862f007e8","acronym":"","url":"https://clinicaltrials.gov/study/NCT03128034","created_at":"2021-01-18T15:24:33.202Z","updated_at":"2025-02-25T16:31:10.471Z","phase":"Phase 1/2","brief_title":"211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia","source_id_and_acronym":"NCT03128034","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sirolimus • fludarabine IV • cyclosporin A microemulsion"],"overall_status":"Recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 10/24/2017","start_date":" 10/24/2017","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 03/31/2029","study_completion_date":" 03/31/2029","last_update_posted":"2025-02-07"},{"id":"83a8f7d9-9fcf-4758-bab6-3b6024965562","acronym":"NCI-2018-01186","url":"https://clinicaltrials.gov/study/NCT03147612","created_at":"2022-04-24T08:58:28.491Z","updated_at":"2025-02-25T16:31:11.081Z","phase":"Phase 2","brief_title":"Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT03147612 - NCI-2018-01186","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • Iclusig (ponatinib) • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • Truxima (rituximab-abbs) • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 02/08/2018","start_date":" 02/08/2018","primary_txt":" Primary completion: 02/28/2027","primary_completion_date":" 02/28/2027","study_txt":" Completion: 02/28/2027","study_completion_date":" 02/28/2027","last_update_posted":"2025-02-07"},{"id":"b88cc8bc-838d-43e3-8862-07db1c3a612f","acronym":"SWOG-S1318","url":"https://clinicaltrials.gov/study/NCT02143414","created_at":"2021-01-18T09:57:21.812Z","updated_at":"2025-02-25T16:36:22.860Z","phase":"Phase 2","brief_title":"Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT02143414 - SWOG-S1318","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABL1 • BCR • PDGFRA • FGFR • PDGFRB • CD4 • CSF1R","pipe":" | ","alterations":" ABL2 fusion","tags":["ABL1 • BCR • PDGFRA • FGFR • PDGFRB • CD4 • CSF1R"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ABL2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • Blincyto (blinatumomab) • methotrexate • vincristine • prednisone • mercaptopurine delayed release (DR6MP) • mercaptopurine • Xatmep (methotrexate oral solution)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 06/30/2015","start_date":" 06/30/2015","primary_txt":" Primary completion: 06/01/2022","primary_completion_date":" 06/01/2022","study_txt":" Completion: 10/23/2025","study_completion_date":" 10/23/2025","last_update_posted":"2025-02-06"},{"id":"7c4709ee-03b2-4e5b-b8af-61df0f32ed05","acronym":"NCI-2018-01788","url":"https://clinicaltrials.gov/study/NCT03670966","created_at":"2021-01-18T18:00:29.277Z","updated_at":"2025-02-25T16:44:27.913Z","phase":"Phase 1/2","brief_title":"211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome","source_id_and_acronym":"NCT03670966 - NCI-2018-01788","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-B","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • fludarabine IV • Iomab-B (I-131-apamistamab) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/10/2019","start_date":" 07/10/2019","primary_txt":" Primary completion: 06/28/2027","primary_completion_date":" 06/28/2027","study_txt":" Completion: 03/20/2029","study_completion_date":" 03/20/2029","last_update_posted":"2025-02-05"},{"id":"33da474f-b112-4a34-ad2b-bf3aa8c54e06","acronym":"AALL1231","url":"https://clinicaltrials.gov/study/NCT02112916","created_at":"2021-01-18T09:46:35.591Z","updated_at":"2025-02-25T16:51:23.270Z","phase":"Phase 3","brief_title":"Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma","source_id_and_acronym":"NCT02112916 - AALL1231","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • CD8 • CD22 • CD34 • CD5 • CD7 • CD2 • MPO","pipe":" | ","alterations":" CD22 expression","tags":["CD20 • CD8 • CD22 • CD34 • CD5 • CD7 • CD2 • MPO"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • bortezomib • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 847","initiation":"Initiation: 10/04/2014","start_date":" 10/04/2014","primary_txt":" Primary completion: 03/31/2020","primary_completion_date":" 03/31/2020","study_txt":" Completion: 09/18/2025","study_completion_date":" 09/18/2025","last_update_posted":"2025-02-04"},{"id":"a5f14953-ab61-4581-b513-a86ad8a1e2b8","acronym":"AALL0434","url":"https://clinicaltrials.gov/study/NCT00408005","created_at":"2021-01-17T17:29:32.376Z","updated_at":"2025-02-25T16:50:52.092Z","phase":"Phase 3","brief_title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma","source_id_and_acronym":"NCT00408005 - AALL0434","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • CD8 • CD22 • CD34 • CD5 • CD7 • CD2 • MPO","pipe":" | ","alterations":" CD22 expression","tags":["CD20 • CD8 • CD22 • CD34 • CD5 • CD7 • CD2 • MPO"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • vincristine • daunorubicin • dexamethasone • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • nelarabine • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Kidrolase (L-asparaginase) • Leunase (L-asparaginase) • Spectrila (asparaginase Escherichia coli) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexamethasone injection"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1895","initiation":"Initiation: 01/22/2007","start_date":" 01/22/2007","primary_txt":" Primary completion: 09/30/2017","primary_completion_date":" 09/30/2017","study_txt":" Completion: 03/07/2025","study_completion_date":" 03/07/2025","last_update_posted":"2025-02-04"},{"id":"5721b478-7256-41e9-bdb4-f8b5fa921a9d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05418088","created_at":"2022-06-14T21:56:15.500Z","updated_at":"2025-02-25T17:01:57.164Z","phase":"Phase 1","brief_title":"Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies","source_id_and_acronym":"NCT05418088","lead_sponsor":"Sumithira Vasu","biomarkers":" CD20 • CD19 • CD22","pipe":" | ","alterations":" CD20 positive","tags":["CD20 • CD19 • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • TriCAR19.20.22 T cells"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 06/30/2022","start_date":" 06/30/2022","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 07/31/2026","study_completion_date":" 07/31/2026","last_update_posted":"2025-02-03"},{"id":"50180a34-f827-4af8-ae52-29b514c2e08b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03512405","created_at":"2021-01-18T17:17:18.091Z","updated_at":"2025-02-25T17:36:00.408Z","phase":"Phase 1/2","brief_title":"Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT03512405","lead_sponsor":"City of Hope Medical Center","biomarkers":" PD-L1","pipe":" | ","alterations":" CD19 positive","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Blincyto (blinatumomab)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 08/02/2019","start_date":" 08/02/2019","primary_txt":" Primary completion: 10/30/2025","primary_completion_date":" 10/30/2025","study_txt":" Completion: 10/30/2025","study_completion_date":" 10/30/2025","last_update_posted":"2025-01-29"},{"id":"770b6fe5-e7bb-4e08-b58f-bc15ae4f95a0","acronym":"NCI-2018-01078","url":"https://clinicaltrials.gov/study/NCT03263572","created_at":"2021-06-08T16:52:54.067Z","updated_at":"2025-02-25T14:50:41.961Z","phase":"Phase 2","brief_title":"Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT03263572 - NCI-2018-01078","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Iclusig (ponatinib) • Blincyto (blinatumomab) • methotrexate • Starasid (cytarabine ocfosfate)"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 11/29/2017","start_date":" 11/29/2017","primary_txt":" Primary completion: 11/30/2025","primary_completion_date":" 11/30/2025","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2024-12-10"},{"id":"9f7f9253-08cf-4953-b6cf-4724356c6c74","acronym":"","url":"https://clinicaltrials.gov/study/NCT04938115","created_at":"2021-06-24T16:52:55.621Z","updated_at":"2024-07-02T16:34:25.693Z","phase":"","brief_title":"Cell Therapy for CD7 Positive Acute Myeloid Leukemia or Mixed Lineage Leukemia","source_id_and_acronym":"NCT04938115","lead_sponsor":"Hebei Senlang Biotechnology Inc., Ltd.","biomarkers":" CD7","pipe":"","alterations":" ","tags":["CD7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • SENL101"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 05/10/2021","start_date":" 05/10/2021","primary_txt":" Primary completion: 05/31/2023","primary_completion_date":" 05/31/2023","study_txt":" Completion: 10/30/2023","study_completion_date":" 10/30/2023","last_update_posted":"2024-06-14"},{"id":"15d10f06-e62d-4c96-9c37-1d6b5cfefc74","acronym":"NCI-2014-01707","url":"https://clinicaltrials.gov/study/NCT02199184","created_at":"2021-01-18T10:16:59.275Z","updated_at":"2024-07-02T16:34:27.417Z","phase":"Phase 2","brief_title":"Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT02199184 - NCI-2014-01707","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • Arzerra (ofatumumab) • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Novex (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 01/14/2015","start_date":" 01/14/2015","primary_txt":" Primary completion: 02/17/2023","primary_completion_date":" 02/17/2023","study_txt":" Completion: 02/17/2023","study_completion_date":" 02/17/2023","last_update_posted":"2024-06-11"},{"id":"75104445-162f-444f-84ea-8038034ab832","acronym":"","url":"https://clinicaltrials.gov/study/NCT02727803","created_at":"2021-01-18T13:21:10.406Z","updated_at":"2024-07-02T16:34:36.895Z","phase":"Phase 2","brief_title":"Personalized NK Cell Therapy in CBT","source_id_and_acronym":"NCT02727803","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" FLT3 • BCL2","pipe":" | ","alterations":" FLT3 mutation","tags":["FLT3 • BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • clofarabine • melphalan • Truxima (rituximab-abbs) • fludarabine IV • Riabni (rituximab-arrx) • busulfan • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • Novex (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 05/19/2016","start_date":" 05/19/2016","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 05/31/2025","study_completion_date":" 05/31/2025","last_update_posted":"2024-06-10"}]